Please check your internet connection and try again.
# Methycobalime (methylcobalamin)
## Overview
Methycobalime is an injectable form of methylcobalamin, an active coenzyme form of vitamin B12. It is primarily used for vitamin B12 deficiency and related neurological disorders.
## Primary Indications
* Treatment of vitamin B12 deficiency.
* Neurological disorders associated with vitamin B12 deficiency, such as pernicious anemia and other megaloblastic anemias.
* Peripheral neuropathy.
## Adult Dosing
* **Initial treatment of deficiency:** Typically 1000 mcg intramuscularly daily for one week, followed by 1000 mcg intramuscularly twice weekly for one month.
* **Maintenance:** 1000 mcg intramuscularly once a month.
* **Dosing for neurological symptoms:** May vary based on severity and response; often starts with higher frequency injections. Specific dosing depends on local protocol.
## Pediatric Dosing
* Dosing in pediatric patients is not well-established and should be determined by a specialist. Generally, doses are lower than adults and depend on age and weight.
## Dose Adjustments
* No dose adjustment is typically required for renal or hepatic impairment.
## Contraindications
* Hypersensitivity to cobalamin or any component of the formulation.
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, headache, rash, itching.
* **Rare:** Anaphylaxis, polycythemia vera exacerbation, pulmonary edema.
## Key Drug Interactions
* **Chloramphenicol:** May interfere with the hematologic response to vitamin B12.
* **Folic acid:** High doses of folic acid may mask the hematologic signs of vitamin B12 deficiency, potentially leading to irreversible neurological damage.
## Monitoring
* Complete blood count (CBC).
* Serum vitamin B12 levels.
* Neurological examination, if indicated.
## Clinical Pearls
* Methylcobalamin is the active form of vitamin B12 and does not require conversion in the body, unlike cyanocobalamin.
* Intramuscular administration is preferred for treating significant deficiency to ensure adequate absorption.
* Long-term therapy may be required for individuals with malabsorption syndromes or specific dietary restrictions.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols for definitive guidance.
